Clinical Use of Infliximab Trough Levels and Antibodies to Infliximab in Pediatric Inflammatory Bowel Disease Patients.

Objective: Optimizing infliximab treatment in pediatric inflammatory bowel disease (IBD) patients by utilizing serum infliximab (IFX) trough levels and antibodies to IFX is recommended. There is need for studies assessing this strategy in clinical practice. Methods: We retrospectively identified all pediatric IBD patients (n = 146, median age 14.8) treated with IFX at our tertiary referral center 2003-2014. All analyzed IFX trough levels (S-IFX, n = 475) and IFX antibody (IFX-Ab, n = 219) titers were included. Both were analyzed using ELISA. We correlated these parameters with concurrently analyzed fecal calprotectin levels and the treatment outcome. Results: If IFX had no efficacy, or a loss of response occurred, 40/64 (63%) had trough levels

from Gastroenterology via xlomafota13 on Inoreader http://ift.tt/26Z5uNR
via IFTTT